Literature DB >> 1541844

Anti-type II collagen ELISA. Increased disease specificity following removal of anionic contaminants from salt-fractionated type II collagen.

R O Williams1, D G Williams, R N Maini.   

Abstract

The purification of type II collagen, for the detection of anti-type II collagen antibodies by ELISA procedures, involves removal of proteoglycans by guanidine-HCl, followed by pepsin solubilisation and salt fractionation. However, type II collagen purified in this way may contain contaminants, despite the apparent purity on SDS-polyacrylamide gels. In this paper we demonstrate how additional purification by DEAE chromatography reduces the degree of background binding in the type II collagen ELISA, leading to an increase in disease specificity. The contaminants included proteoglycan and bound serum IgG from both rheumatoid arthritis (RA) patients and healthy controls in ELISA. Furthermore, positive correlations were observed in the sera (n = 24) between degree of reactivity to the contaminants and to (1) purified proteoglycan (r = 0.50, P = 0.01) and (2) pepsin (r = 0.65, P = 0.001). Thus, inadequate purification of type II collagen produces false positive reactions in the collagen ELISA and gives rise to a high background. A lack of specificity has been frequently associated with this assay.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541844

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

2.  An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis.

Authors:  M Walmsley; D M Butler; L Marinova-Mutafchieva; M Feldmann
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

3.  Antibodies against 4 Atypical Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis.

Authors:  Lorena Rodríguez-Martínez; Cristina Regueiro; Sámer Amhaz-Escanlar; Carmen Pena; Paloma Herbello-Hermelo; Antonio Moreda-Piñeiro; Javier Rodriguez-Garcia; Antonio Mera-Varela; Eva Pérez-Pampín; Antonio González
Journal:  Diagnostics (Basel)       Date:  2022-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.